Company intelligence / Profile preview

Tikva Allocell

Ownership: Private
Employees: ~14
Development stage: Preclinical

Overview

The company has published research on Novel OX40 and 4-1BB Derived Spacers that enhance CD30 CAR activity and safety in CD30 positive lymphoma models. They are developing B7-H3-targeting CAR-T cells for solid tumors and preparing for IND submission for their lead candidate.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyAllogeneic EBV-Specific T cell (ALLO EBVST) therapy
Industry: Biotech

Drug pipeline

4 assets

TAVST-02

Preclinical

3 more assets in the full pipeline.

Partnerships

Baylor College of MedicineA*STAR's Institute of Molecular and Cell Biology

Beyond the preview

Go deeper on Tikva Allocell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tikva Allocell.